The Experts below are selected from a list of 267 Experts worldwide ranked by ideXlab platform
Itzhak Kronzon - One of the best experts on this subject based on the ideXlab platform.
-
Primary Prevention of Ischemic Stroke
Circulation, 2001Co-Authors: Paul A. Tunick, Itzhak KronzonAbstract:To the Editor: In the American Heart Association’s Scientific Statement on the Primary Prevention of Ischemic Stroke,1 the committee …
Paul A. Tunick - One of the best experts on this subject based on the ideXlab platform.
-
Primary Prevention of Ischemic Stroke
Circulation, 2001Co-Authors: Paul A. Tunick, Itzhak KronzonAbstract:To the Editor: In the American Heart Association’s Scientific Statement on the Primary Prevention of Ischemic Stroke,1 the committee …
A. Santaballa - One of the best experts on this subject based on the ideXlab platform.
-
SEOM clinical guidelines to Primary Prevention of cancer (2018)
Clinical and Translational Oncology, 2019Co-Authors: J. Bayo, R. Molina, J. Pérez, E. Pérez-ruíz, J. Aparicio, C. Beato, J. P. Berros, M. Bolaños, B. Graña, A. SantaballaAbstract:Cancer is the leading social and healthcare problem of the twenty-first century. The aim of Primary Prevention is to decrease the incidence of cancer by avoiding the known causes and risk factors. Nevertheless, it has been estimated that cancer diagnoses could be halved through Primary Prevention measures. A comprehensive review of the scientific evidence regarding the main carcinogens and risk factors and Primary Prevention recommendations have been put forth based on this evidence. The GRADE scale has been used to classify the grade of evidence. We present the scientific evidence and recommendations for Primary Prevention of the major modifiable risk factors: smoking, alcohol, diet, obesity, physical activity, occupational and environmental factors, ultraviolet radiation, infections, and socioeconomic factors. Primary Prevention is a simple, effective means to lower the incidence of cancer. Preventive measures must be circulated in the fight against cancer.
-
SEOM clinical guidelines to Primary Prevention of cancer (2018).
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexic, 2019Co-Authors: J. Bayo, R. Molina, E. Pérez-ruíz, J. Aparicio, C. Beato, J. P. Berros, M. Bolaños, B. Graña, Juan Saúl Barajas Pérez, A. SantaballaAbstract:Cancer is the leading social and healthcare problem of the twenty-first century. The aim of Primary Prevention is to decrease the incidence of cancer by avoiding the known causes and risk factors. Nevertheless, it has been estimated that cancer diagnoses could be halved through Primary Prevention measures. A comprehensive review of the scientific evidence regarding the main carcinogens and risk factors and Primary Prevention recommendations have been put forth based on this evidence. The GRADE scale has been used to classify the grade of evidence. We present the scientific evidence and recommendations for Primary Prevention of the major modifiable risk factors: smoking, alcohol, diet, obesity, physical activity, occupational and environmental factors, ultraviolet radiation, infections, and socioeconomic factors. Primary Prevention is a simple, effective means to lower the incidence of cancer. Preventive measures must be circulated in the fight against cancer.
Subramoniam Madhusoodanan - One of the best experts on this subject based on the ideXlab platform.
-
Primary Prevention of psychiatric illness in special populations.
Annals of Clinical Psychiatry, 2010Co-Authors: Martha Sajatovic, Renata Sanders, Lada Alexeenko, Subramoniam MadhusoodananAbstract:BACKGROUND Some populations appear to be particularly vulnerable to the development of psychiatric symptomatology related to life events and biologic or social/cultural factors. Such groups include individuals who have experienced traumatic events, military personnel, individuals with serious medical conditions, postpartum women, and immigrants. This study reviews the literature regarding Primary Prevention of psychiatric disorders in special populations and identifies a variety of universal, selective, and indicated Prevention measures aimed at minimizing the psychiatric sequelae in these groups. METHODS The authors reviewed the literature regarding the Prevention of psychiatric symptoms in trauma/abuse victims, individuals in the military, oncology patients, patients with diabetes, pregnant/postpartum women, and immigrants. RESULTS The literature on Primary Prevention of psychiatric illness in the special populations identified is rather limited. Universal Prevention may be beneficial in some instances through public awareness campaigns and disaster planning. In other instances, more specific and intensive interventions for individuals at high risk of psychiatric illness may improve outcomes, for example, crisis counseling for those who have experienced severe trauma. CONCLUSIONS Primary Prevention of psychiatric illness may be an attainable goal via implementation of specific universal, selected, and indicated Primary Prevention measures in special populations.
Heidi Stürzlinger - One of the best experts on this subject based on the ideXlab platform.
-
The use of statins in Primary Prevention.
GMS health technology assessment, 2006Co-Authors: Ingrid Rosian, Ernest Pichlbauer, Heidi StürzlingerAbstract:BACKGROUND The use of statins in secondary Prevention of cardiovascular events is well established. However, there is ongoing discussion about the use of statins in the context of Primary Prevention. Moreover statins - besides cholesterol-lowering effects - are assumed to have pleiotropic effects. Positive impacts on diseases like stroke, Alzheimer's disease or osteoporosis are discussed but still have to be proven. OBJECTIVES The aim of this report is first to investigate the efficacy and effectiveness of statins in Primary Prevention of cardiovascular and non-cardiovascular events and second to examine the economic implications for Germany - particularly in comparison to existing Prevention programs. Finally ethical questions are considered. METHODS A systematic literature search was performed for the period between 1998 and 2004 which yielded 3704 abstracts. Overall 43 articles were included for assessment and 167 for background information, according to predefined selection criteria. RESULTS Most studies within the context of Primary Prevention describe significant risk reductions with regard to cardiovascular events; yet no significant results according to the reduction of the overall mortality rate can be seen. With respect to stroke, osteoporosis and Alzheimer's disease results are inconsistent. Regarding cost-effectiveness of Primary Prevention with statins results turn out to be inconsistent as well or even negative for populations with low to moderate risk. For groups with high cardiovascular risk the intervention is mostly assessed to be cost-effective. No cost-effectiveness study for Germany was found. According to a rough estimate of future expenses statin drug expenses of the German legal health insurance might increase at least by 50% in the case of an enlargement of the group of recipients. DISCUSSION To thoroughly estimate the cost-effectiveness of the use of statins in Primary Prevention in Germany a model calculation including all relevant parameters has to be done. Moreover - from the economic as well as from the ethic point of view - one of the most important issues in Primary Prevention therapy is the question of compliance. The amount of risk reduction seen in Primary Prevention studies can be achieved only if patients as well as doctors follow therapeutic instructions and medical guidelines (as for example the guidelines of the "Adult Treatment Panel III", the "European guidelines on cardiovascular disease Prevention in clinical practice" or the guidelines of the German Association of Cardiology and of the "Arzneimittelkommission der deutschen Arzteschaft fur Koronare Herzkrankheit"). CONCLUSION For (Primary) Prevention of cardiovascular diseases the use of statins as suggested in guidelines is recommended - provided that these guidelines are scientifically evaluated at regular intervals. Regarding stroke, osteoporosis and Alzheimer's disease definite conclusions cannot be drawn at present. Particular attention has to be paid to the problem of compliance both in statin-therapy as well as in alternative therapies. The cost-effectiveness of Primary Prevention with statins mainly depends on the development of statin prices.
